Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
DETAILED ACTION
Continued Examination Under 37 CFR 1.114
A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 6/26/2026 has been entered.
Status of 17/770,264
Claims 1-10, 12-13, 21-22, 24, and 26-29 are currently pending.
Priority
Instant application 17/770,264, filed 4/19/2022, claims priority as follows:
PNG
media_image1.png
57
391
media_image1.png
Greyscale
Support for the instant claims is found in the provisional application.
Response to Applicant’s Arguments/Amendments
The amendment filed 6/26/2026 has been entered. No claims have been amended, cancelled, or added.
Claims 8-10, 12-13, 26-27, and 29 were rejected under 35 U.S.C. 103 in the Final dated 2/26/2026. In response, Applicant argues the elected species is not a compound of Broad’s formula (I) because Broad makes clear that all of R4-R7 cannot be hydrogen regardless of the exemplary compounds taught by Broad. Applicant’s arguments have been considered, and are considered persuasive. Thus, the rejection is overcome and withdrawn.
However, new ground(s) of rejection presented in this Office Action.
Election/Restriction
Applicant’s election of Group II, claims 8-13 and 26-29, drawn to methods of treating a parasitic disease caused by a parasite from the genus Cryptosporidium, in the reply filed 5/14/2025 is acknowledged. Applicant’s election of compound 16:
PNG
media_image2.png
202
260
media_image2.png
Greyscale
in the reply filed 5/14/2025, is also acknowledged. Because Applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.01(a)).
Examination will begin with the elected species. In accordance with MPEP § 803.02, if upon examination of the elected species, no prior art is found that would anticipate or render obvious the instant invention based on the elected species, the search of the Markush-type claim will be extended. If prior art is then found that anticipates or renders obvious the non- elected species, the Markush-type claim will be rejected. It should be noted that the prior art search will not be extended unnecessarily to cover all non-elected species. Should Applicant overcome the rejection by amending the claim, the amended claim will be examined again. The prior art search will be extended to the extent necessary to determine patentability of the Markush-type claim. In the event prior art is found during further examination that renders obvious or anticipates the amended Markush-type claim, the claim will be rejected and the action made final.
In the Non-Final Rejection dated 6/12/2025, the elected species was searched and prior art was identified. During the search, the scope of the elected species search was expanded to include additional variables of instant R4 and R5 and an additional 102 rejection was identified. Both rejections of the elected and expanded species have been overcome. The scope of the search was then expanded to compounds of Formulae (I) and (IV) where R1 is aryl, L1 is -CΞC-, A1 is CH, A2 is CH, L2 is -C(O)NR-, where R is hydrogen, R2 is a substituted aryl, L3 is absent, R3 is hydrogen, L4 is alkylene, R4 is -N(R)2, where R is alkyl, R5 is hydrogen, R6 is hydrogen, --- is a double bond, m is 1, n is 1, and R7 is hydrogen and an additional expanded species of Formula (I) and (IV) where R1 is aryl, L1 is -CΞC-, A1 is CH, A2 is CH, L2 is -C(O)NR-, where R is hydrogen, R2 is a substituted aryl, L3 is absent, R3 is hydrogen, L4 is alkylene, R4 is -OH, R5 is hydrogen, R6 is hydrogen, --- is a single bond, m is 1, n is 1, and R7 is hydrogen. The full scope of the claims has not yet been searched in accordance with Markush search practice. Claims 8-10, 26-27, and 29 read on the expanded species. The scope of claims 12 and 13 was searched and no art was identified, and thus the claims are objected to. Claims 1-7, 21-22, 24, and 28 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to nonelected species and/or group, there being no allowable generic or linking claim.
NEW REJECTIONS
Claim Rejections - 35 USC § 112(b)
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
Claims 8 and 27 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention.
Claims 8 and 27 recite, “R7 is -CH2OR8; wherein R8 is alkyl having one or more optional points of substitution;”. However, the claims previously recite that R7 can be hydrogen, -CH2OH, or -CH2OR and do not previously recite an R8 variable. Thus, the limitation of R7 is indefinite and unclear. Appropriate correction is required.
Claim 27 recites a broader scope of R1 than that of claim 26, the claim from which 27 depends. Thus, there is insufficient antecedent basis for these limitations in the claim. Appropriate correction is required.
Claim Rejections - 35 USC § 102
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
(a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention.
Claims 26 and 29 are rejected under 35 U.S.C. 102(a)(1) and 102(a)(2) as being anticipated by The Broad Institute, Inc. (WO 2018/175385 A1, cited in the IDS of 4/19/2022, herein after “Broad”). This rejection applies to an expanded species.
The reference Broad discloses compounds useful for the treatment of parasitic diseases (abstract), and specifically discloses compound E4 (page 21):
PNG
media_image3.png
207
486
media_image3.png
Greyscale
Which is used in a method of inhibiting or preventing the growth of parasites from C. parvum in the inoculation medium RPMI 1640 (page 141, lines 7-9) and was found to have an EC50 of 68 nm (page 141, Table 5). Compound E4 anticipates a compound of instant Formula (IV) of claim 26:
PNG
media_image4.png
177
220
media_image4.png
Greyscale
When R1 is aryl, L1 is -CΞC-, A1 is CH, A2 is CH, L2 is -C(O)NR-, where R is hydrogen, R2 is a substituted aryl, L3 is absent, R3 is hydrogen, L4 is alkylene, R4 is -N(R)2, where R is alkyl, R5 is hydrogen, R6 is hydrogen, --- is a double bond, m is 1, n is 1, and R7 is hydrogen. Thus, Broad anticipates claims 26 and 29.
Claim Rejections - 35 USC § 103
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows:
1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.
This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention.
Claims 8-10, 26-27, and 29 are rejected under 35 U.S.C. 103 as being unpatentable over The Broad Institute, Inc. (WO 2018/175385 A1, cited in the IDS of 4/19/2022, herein after “Broad”). This rejection applies to an expanded species.
Determining the scope and contents of the prior art
The reference Broad teaches as disclosed above and at least those teachings are incorporated herein. In addition to compound E4, Broad teaches that compound E27:
PNG
media_image5.png
218
475
media_image5.png
Greyscale
is also active against C. parvum (page 141):
PNG
media_image6.png
287
352
media_image6.png
Greyscale
.
Compound E27 partially maps to a compound of instant formulae (I) and (IV):
PNG
media_image4.png
177
220
media_image4.png
Greyscale
When R1 is aryl, L1 is -CΞC-, A1 is CH, A2 is CH, L2 is -C(O)NR-, where R is hydrogen, R2 is a substituted aryl, L3 is absent, R3 is hydrogen, L4 is alkylene, R4 is -OH, R6 is hydrogen, --- is a single bond, m is 1, n is 1, and R7 is hydrogen.
The compound E27 differs from a compound of the instant method claims by the presence of an alkyl amine substituent on the diazacyclooctane, specifically in the R5 position of the instant formulae. The instant formulae require that R5 and R6 be hydrogen.
However, Broad teaches that compounds of the disclosure are believed to inhibit the growth of or kill a parasitic protozoan that causes malaria and/or cryptosporidiosis (page 31, lines 21-25), and includes compounds that fall under this definition but not tested in the specific cryptosporidiosis assay. Such compounds include E35 (page 28):
PNG
media_image7.png
201
484
media_image7.png
Greyscale
Which differs from compound E27 by the lack of alkyl amine in the R5 position, and the presence of an alkyl group adjacent to the R5 site. Stated briefly, compound E27 teaches a compound where R6 is hydrogen, and the sites on the diazacyclooctane adjacent to R5 and R6 are hydrogen, whereas compound E35 teaches a compound where R5, R6, and the site on the diazacyclooctane adjacent to R6 is hydrogen.
Ascertaining the differences between the prior art and the claims at issue
The reference Broad fails to teach an anticipatory species in a method of treatment or prophylaxis of a parasitic disease caused by a parasite from the genus Cryptosporidium.
Resolving the level of ordinary skill in the pertinent art
The level of ordinary skill in the art is represented by an artisan who has sufficient background in the development of Cryptosporidium treatment methods with azetidine-based compounds. An artisan possesses the technical knowledge necessary to make adjustments to the azetidine-based compounds to enhance their effectiveness in the treatment methods. Said artisan has also reviewed the problems in the art as regards to use of said Cryptosporidium treatment methods with azetidine-based compounds and understands the solutions that are widely known in the art.
Considering objective evidence present in the application indicating obviousness or nonobviousness
Applying KSR prong (B), it would have been prima facie obvious to one of ordinary skill in the art to substitute the alkyl amine moiety of Compound E27 of Broad with the hydrogen at the same site of compound E35 because the compounds are known for the same purpose. Structurally similar compounds are expected to have similar properties. A skilled artisan would be motivated before the effective filing date to make such a substitution to identify additional compounds additional of treating Cryptosporidiosis. The same person of ordinary skill would have reasonably predicted success in light of the teachings of Broad.
Claim Objections
Claims 12 and 13 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.
Conclusion
Claims 8-10, 26-27, and 29 are rejected. Claims 12 and 13 are objected to. Claims 1-7, 21-22, 24, and 28 are withdrawn.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to Kendall Heitmeier whose telephone number is (703)756-1555. The examiner can normally be reached Monday-Friday 8:30AM-5:00PM ET.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Clinton Brooks can be reached at 571-270-7682. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/K.N.H./Examiner, Art Unit 1621
/CLINTON A BROOKS/Supervisory Patent Examiner, Art Unit 1621